前庭型メニエール病に対するプロスタグランディンI2誘導体の治療効果

書誌事項

タイトル別名
  • Effects of Prostaglandin I2 Derivative on Symptoms in Patients with Vestibular Meniere's Disease

この論文をさがす

抄録

We treated 44 cases of vestibular Ménière's disease with prostaglandin I2 (PGI2), a vasodialator, at a dose of 120μg per day for more than two months (mean: 8.0 months). The long-term administration of constant daily amounts of PGI2 attained good long-term results in vertigo according to the criteria of the Japan Society for Equilibrium Research. The results were as follows: the administration of PGI2 completely controlled vertigo in 65.9% (29/44) and improved it in 29.5% (13/44); however, four cases suffered from the typical type of Meniere's disease thereafter (9.1%: 4/44). The objective findings of nystagmus were also reduced in 85.7% (24/28) after PGI2 treatments.<BR>PGI2 was significantly more effective in patients with a vertigo duration within 120 min and -SP/AP negative results on electro-cochleogram (ECoG) than the others. On the contrary, patients with a vertigo duration of more than 120 min and -SP/AP positive results on ECoG experienced cochlear symptoms together with vertiginous sensations later. These patients should be treated with an oral osmotic diuretic, isosorbide. These findings suggest that cases presently diagnosed as vestibular Ménière's disease could include at least two kinds of oto-pathologies; vascular disease and endolymphatic hydrops.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (8)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ